top of page
HOME
ABOUT US
OUR CHALLENGE
OUR MISSION
OUR PIPELINE
OUR PUBLICATIONS
OUR PATENTS
OUR TEAM
ATXA Team
Advisory Team
Board of Directors
Careers
NEWS
PAH-ADVANCE
CONTACT
More
Use tab to navigate through the menu items.
FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAH
DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
Mar 8, 2018
COMPANY UPDATES
bottom of page
